MP Advisors

MP Advisors is a Consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia. It was operating earlier as an international affiliate of Mehta Partners LLC since 1996. Today it has a highly motivated, qualified team of PhD's, MBA's and Pharmacist who apply their domain knowledge to develop proprietary data bases, understand dynamic regulatory laws across geographies, track and analyze latest trends in drug development, clinical trials and specific diseases. MP Advisors has insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.

...Show More ...Show Less

2 Reports from MP Advisors

Sort by:

Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward

Jul 03, 2020 | Published by: MP Advisors | USD 4,500

Outlook of Diabetic Macular Edema – Current Landscape and the Way Forward Global market for DME was ~$3.7 billion in 2019 with US alone contributing to 51% market share, owing to the higher incidence rates of diabetes amongst the developed nations. In 2018, ~2.4m people in the US had DME, of that on ... Read More
Japan Biosimilars: Landscape Today, Outlook Tomorrow

Jan 06, 2020 | Published by: MP Advisors | USD 4,500

Japan Biosimilars: Landscape Today, Outlook Tomorrow ‘Biosame’ entry, uninterrupted supply and companies’ strong frontend footprint requirements make it a distinct market After a decade, JP Biosimilar guidelines’s first revision expected in FY2020 Demonstrate Chuikyo need of biosimilar tool to curb ... Read More